ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.620
-0.050 (-1.87%)
Dec 20, 2024, 4:00 PM EST - Market closed
ImmunityBio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 7.33 | 0.62 | 0.24 | 0.93 | 0.61 | 2.2 | Upgrade
|
| Revenue Growth (YoY) | 1218.71% | 159.17% | -74.30% | 54.38% | -72.52% | -30.25% | Upgrade
|
| Gross Profit | 7.33 | 0.62 | 0.24 | 0.93 | 0.61 | 2.2 | Upgrade
|
| Selling, General & Admin | 164.76 | 135.32 | 108.71 | 126.76 | 61.02 | 46.46 | Upgrade
|
| Research & Development | 201.85 | 226.67 | 242.2 | 191.6 | 140.26 | 112.06 | Upgrade
|
| Operating Expenses | 366.62 | 361.99 | 350.91 | 318.36 | 201.28 | 158.52 | Upgrade
|
| Operating Income | -359.28 | -361.36 | -350.67 | -317.42 | -200.67 | -156.32 | Upgrade
|
| Interest Expense | -148.88 | -129.2 | -63.52 | -14.85 | -9.07 | -5.92 | Upgrade
|
| Interest & Investment Income | 7.27 | 1.13 | - | - | 2.44 | 2.44 | Upgrade
|
| Earnings From Equity Investments | - | -7.55 | -12.11 | -0.8 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -84.55 | -84.44 | 16.91 | 4.81 | 0.02 | -0.53 | Upgrade
|
| EBT Excluding Unusual Items | -585.44 | -581.41 | -409.38 | -328.27 | -207.3 | -160.33 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -13 | -10.3 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.59 | -1.59 | -7.28 | -8.72 | 1.47 | - | Upgrade
|
| Asset Writedown | -0.89 | -0.89 | -0.68 | - | -10.66 | - | Upgrade
|
| Other Unusual Items | -0 | -0 | 0.05 | 0.14 | 0.75 | 0.07 | Upgrade
|
| Pretax Income | -587.92 | -583.89 | -417.29 | -349.84 | -226.03 | -160.26 | Upgrade
|
| Income Tax Expense | -0.04 | -0.04 | 0.03 | 0.01 | -1.85 | -0.11 | Upgrade
|
| Earnings From Continuing Operations | -587.88 | -583.85 | -417.32 | -349.85 | -224.19 | -160.16 | Upgrade
|
| Minority Interest in Earnings | 0.09 | 0.66 | 0.75 | 3.06 | 2.34 | 2.38 | Upgrade
|
| Net Income | -587.79 | -583.2 | -416.57 | -346.79 | -221.85 | -157.78 | Upgrade
|
| Net Income to Common | -587.79 | -583.2 | -416.57 | -346.79 | -221.85 | -157.78 | Upgrade
|
| Shares Outstanding (Basic) | 681 | 509 | 400 | 389 | 377 | 366 | Upgrade
|
| Shares Outstanding (Diluted) | 681 | 509 | 400 | 389 | 377 | 366 | Upgrade
|
| Shares Change (YoY) | 54.09% | 27.19% | 2.74% | 3.23% | 2.93% | 13.36% | Upgrade
|
| EPS (Basic) | -0.86 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | Upgrade
|
| EPS (Diluted) | -0.88 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | Upgrade
|
| Free Cash Flow | -434.1 | -397.34 | -415.67 | -307.98 | -173.39 | -156.4 | Upgrade
|
| Free Cash Flow Per Share | -0.64 | -0.78 | -1.04 | -0.79 | -0.46 | -0.43 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -4900.22% | -58096.95% | -146111.67% | -33985.44% | -33169.09% | -7098.82% | Upgrade
|
| Profit Margin | -8016.83% | -93761.41% | -173569.58% | -37129.55% | -36669.59% | -7165.17% | Upgrade
|
| Free Cash Flow Margin | -5920.55% | -63881.19% | -173196.25% | -32974.52% | -28660.00% | -7102.45% | Upgrade
|
| EBITDA | -341.3 | -342.85 | -332.41 | -303.19 | -187.93 | -142.27 | Upgrade
|
| D&A For EBITDA | 17.98 | 18.51 | 18.26 | 14.24 | 12.74 | 14.04 | Upgrade
|
| EBIT | -359.28 | -361.36 | -350.67 | -317.42 | -200.67 | -156.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.